Abstract：C1q nephropathy is a rare type of glomerulonephritis manifested as the deposition of C1q in the glomerular mesangium during immunofluorescent staining. Systemic lupus erythematosus and type I membranoproliferative glomerulonephropathy need to be excluded in the diagnosis of C1q nephropathy. C1q nephropathy has various manifestations under a light microscope, mainly including minimal change disease, focal segmental glomerulosclerosis, and proliferative glomerulonephritis. This disease is mainly manifested as persistent proteinuria or nephrotic syndrome and occurs more frequently in boys. Currently, glucocorticoids are mainly used for the treatment of this disease. Patients with C1q nephropathy show a good response to immunosuppressant treatment, but have a high rate of glucocorticoid resistance. Therefore, in this case, methylprednisolone pulse therapy or a combination with immunosuppressant treatment helps to achieve a good prognosis.
Gunasekara VN,Sebire NJ,Tullus K.C1q nephropathy in children:clinical characteristics and outcome[J].Pediatr Nephrol,2014,29(3):407-413.
[5]
Wenderfer SE,Swinford RD,Braun MC.C1q nephropathy in the pediatric population:pathology and pathogenesis[J].Pediatr Nephrol,2010,25(8):1385-1396.
[6]
van den Dobbelsteen ME,van der Woude FJ,Schroeijers WE,et al.Both IgG-and C1q-receptors play a role in the enhanced binding of IgG complexes to human mesangial cells[J].J Am Soc Nephrol,1996,7(4):573-581.
[7]
Malleshappa P.C1q nephropathy-unity in diversity[J].J Renal Inj Prev,2013,2(4):117-118.
[8]
Chaves J,Beirão I,Balreira A,et al.Progressive myoclonus epilepsy with nephropathy C1q due to SCARB2/LIMP-2 deficiency:clinical report of two siblings[J].Seizure,2011,20(9):738-740.
[9]
Ma R,Cui Z,Hu SY,et al.The alternative pathway of complement activationmay be involved in the renal damage of human anti-glomerular basement membrane disease[J].PLoS One,2014,9(3):e91250
[10]
Boqari DT,Al Faraj S,Arafah M,et al.Herb-induced acute bone marrow intoxication and interstitial nephritis superimposing glomerular C1q deposition in a patient with paroxysmal nocturnal hemoglobinuria[J].Saudi J Kidney Dis Transpl,2015,26(3):572-579.
[11]
Tibor Fülöp T,CsongrádiÉ,Lerant AA,et al.Resolution of C1q deposition but not of the clinical nephrotic syndrome after immunomodulating therapy in focal sclerosis[J].J Nephropathol,2015,4(2):54-58.
GalešićK,HorvatićI,BatinićD,et al.C1Q Nephropathy:case reports and literature review[J].Lijec Vjesn,2015,137(9-10):283-287.
[20]
Reeves-Daniel AM,Iskandar SS,Bowden DW,et al.Is collapsing C1q nephropathy another MYH9-associated kidney disease? A case report[J].Am J Kidney Dis,2010,55(5):e21-24.
[21]
Zhao Y,Fan H,Bao BY,et al.C1q nephropathy in an old woman with acute renal failure:a case report and literature review[J].Ren Fail,2014,36(7):1136-1138.
[22]
Mokhtar GA,Jalalah SM.A Clinicopathological study of C1q nephropathy at King Abdulaziz University[J].Iran J Kidney Dis,2015,9(4):279-285.
Wenderfer SE,Swinford RD,Braun MC.C1q nephropathy in the pediatric population:pathology and pathogenesis[J].Pediatr Nephrol,2010,25(8):1385-1396.
[29]
Gunasekara VN,Sebire NJ,Tullus K.C1q nephropathy in children:clinical characteristics and outcome[J].Pediatr Nephrol,2014,29(3):407-413.
[30]
Deurwaarder ES,Steenbergen EJ,Hoogeveen EK.et al.Membranous nephropathy with predominance of C1q:another variant of C1q nephropathy[J].Clin Nephrol,2012,77(6):501-504.
[31]
O'Flynn J,Flierman R,van der Pol P,et al.Nucleosomes and C1q bound to glomerular endothelial cells serve as targets for autoantibodies and determine complement activation[J].Mol Immunol,2011,49(1-2):75-83.
[32]
Maliakkal JG,Liapis H,White AJ,et al.C1q nephropathy in the setting of granulomatosis with polyangiitis treated with tacrolimus[J].Clin Kidney J,2014,7(5):499-500.
[33]
Kim J,Patnaik N,Chorny N,et al.Second-line immunosuppressive treatment of childhood nephrotic syndrome:a single-center experience[J].Nephron Extra,2014,4(1):8-17.
Rocha S,Carvalho MJ,Lobato L,et al.C1q nephropathy and malignancy[J].Nefrologia,2012,32(2):270-272.
[36]
Sinha A,Nast CC,Hristea I,et al.Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy[J].Clin Exp Nephrol,2011,15(1):164-170.
Spreitzer MV,Vizjak A,Ferluga D,et al.Do C1q or IgM nephropathies predict disease severity in children with minimal change nephrotic syndrome[J].Pediatric Nephrol,2014,29(1):67-74.
[41]
Kersnik Levart T,Kenda RB,Avgustin CavićM,et al.C1Q nephropathy in children[J].Pediatr Nephrol,2005,20(12):1756-1761.
